Lundbeck

News

Graphic of man flying a white flag against a teal background

Lundbeck bows out of bidding war for Avadel

Lundbeck won't raise its offer to buy Avadel any further, clearing the way for the sleep disorder specialist to complete a merger with Alkermes.

News

Alkermes offers more for Avadel after Lundbeck bid

Alkermes has been forced to raise its offer for narcolepsy drug developer Avadel Pharma, after a rival bid from Lundbeck was deemed superior.

News

Lundbeck makes bid for Avadel, trying to displace Alkermes

Another pharma M&A fight has broken out, with Lundbeck outbidding Alkermes in an attempt to take control of Avadel Pharma and its narcolepsy product.

News

Hands with the world painted on the palms, cloud filled blue sky in the background

Lundbeck retreats from dozens of markets, slashing staff

Lundbeck has announced a major change to its commercial strategy, withdrawing from 27 markets and handing day-to-day operations to partners.

News

Lundbeck president and CEO Charl van Zyl

Lundbeck planning for four novel drugs in phase 3 in 2026

Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from

News

Lundbeck drops in on epilepsy drug with $2.6bn Longboard bid

Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster.

Lundbeck bows out of bidding war for Avadel

Alkermes offers more for Avadel after Lundbeck bid

Lundbeck makes bid for Avadel, trying to displace Alkermes

Lundbeck retreats from dozens of markets, slashing staff

Lundbeck planning for four novel drugs in phase 3 in 2026

Lundbeck drops in on epilepsy drug with $2.6bn Longboard bid

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Lundbeck

Editor's Picks